Components of this pathway, including Wnt ligands (e.g., Wnt1, Wnt2B, Wnt3, Wnt5A, Wnt7B, and Wnt10A), Frizzled receptors (such as FZD2, FZD7, FZD8, and FZD9), downstream effectors such as β-catenin and TCF/LEF transcription factors, and inhibitors such as DKK1, are increasingly recognized as promising diagnostic and prognostic biomarkers in colorectal, gastric, pancreatic, and esophageal cancers. This evidence concerns the gene WNT10A and esophageal cancer.